Legal & General Group
ACRV icon

Legal & General Group’s Acrivon Therapeutics ACRV Stock Holding History

Legal & General Group’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-839
Closed -$1.7K – 3419
2025
Q1 		$1.7K Hold
839
– – ﹤0.01% 3360
2024
Q4 		$5.08K Hold
839
– – ﹤0.01% 3333
2024
Q3 		$5.87K Hold
839
– – ﹤0.01% 3354
2024
Q2 		$4.87K Hold
839
– – ﹤0.01% 3378
2024
Q1 		$5.93K Hold
839
– – ﹤0.01% 3282
2023
Q4 		$4.13K Hold
839
– – ﹤0.01% 3338
2023
Q3 		$8.02K Hold
839
– – ﹤0.01% 3305
2023
Q2 		$10.9K Sell
839
-85
-9% -$1.03K ﹤0.01% 3304
2023
Q1 		$11.7K Buy
+924
New +$15.5K ﹤0.01% 3181

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Legal & General Group's ACRV Position: Q2 2025 in Review

Legal & General Group sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 839 shares — an estimated $1.7K sold.

Legal & General Group first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $11.7K in Q1 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Legal & General Group reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 839 Acrivon Therapeutics shares in Q2 2025, an estimated $1.7K.
  • Legal & General Group first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
  • Legal & General Group's Acrivon Therapeutics position peaked at $11.7K in Q1 2023.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.